Thank you for Subscribing to Life Science Review Weekly Brief
Leland joins Genovac as Vice President of production and characterization.
FREMONT, CA: Pete Leland, a 20-year veteran of the biotechnology sector, joins Genovac Antibody Discovery, Fargo, N.D., as its Vice President of production and characterization.
Genovac is a contract research firm that discovers and develops antibodies for therapeutic, diagnostic, and research markets. The company's core technologies, genetic immunization, advanced hybridoma, and single B cell screening allow rapid antibody discovery against biopharma's most challenging targets. With the appointment of Leland, Genovac can now offer its clients robust production and characterization services.
Pete is an accomplished and recognized pioneer in biotechnology. Genovac is committed to being a one-stop-shop, offering antibody discovery, production, and characterization services. With Pete's expertise and experience, the company has hit the ground running in the United States. Genovac is lucky to have him at the head of a critical part of its scientific team.
Leland heads the group that manufactures and tests antibodies, which Genovac customers use to develop drugs that help fight genetic and infectious diseases like Covid-19, cancer, and neurological disorders.
Genovac is doing cutting-edge work helping pharmaceutical and diagnostic firms across the world. It is very exciting to establish these technologies at the Fargo site while offering scientific career opportunities in the process. Before joining Genovac, Leland was a principal scientist for downstream process development at Catalent, Madison, Wis. Before that, and he was a manager at Patheon, a division of Thermos Fisher Scientific, and the senior manager of technical operations in the Madison, Wis., Protein Division of Fargo-based Aldevron. Leland has a Bachelor of Arts in chemistry from St. Olaf College, Northfield, Minn., and a doctorate in biochemistry from the University of Wisconsin-Madison.
Genovac Antibody Discovery has completed more than 3,500 projects, delivering antibodies to clients in North America, Australia, Europe, and Asia developed into commercial drugs. Genovac has completed about 25 client and internal COVID-19 campaigns and has developed two antibodies that neutralize the U.K., Brazilian, and South African mutations.